Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexei F Kirkin

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Nature Materials|May 26, 2018
Adoptive T cell cancer therapyKarine N Dzhandzhugazyan, Per Guldberg, Alexei F Kirkin
Cancer Investigation|March 21, 2002
Cancer/testis antigens: structural and immunobiological propertiesAlexei F Kirkin, Karine N Dzhandzhugazyan, Jesper Zeuthen
Journal for Immunotherapy of Cancer|December 4, 2025
Adoptive cell transfer therapy with ex vivo primed peripheral lymphocytes in combination with chemotherapy in locally advanced or metastatic triple-negative breast cancer: the ImmunoBreast phase Ib clinical trialOdd Lilleng Gammelgaard, Sidse Ehmsen, Anne Marie Bak Jylling, et al.
Molecular Cancer|January 6, 2024
Adoptive cell transfer therapy with ex vivo primed peripheral lymphocytes in combination with anti-PDL1 therapy effectively inhibits triple-negative breast cancer growth and metastasisOdd L Gammelgaard, Mikkel G Terp, Alexei F Kirkin, et al.
Neuro-Oncology Advances|November 12, 2021
A randomized phase II trial of efficacy and safety of the immunotherapy ALECSAT as an adjunct to radiotherapy and temozolomide for newly diagnosed glioblastomaKatja Werlenius, Giuseppe Stragliotto, Michael Strandeus, et al.
Nature Communications|March 8, 2018
Adoptive cancer immunotherapy using DNA-demethylated T helper cells as antigen-presenting cellsAlexei F Kirkin, Karine N Dzhandzhugazyan, Per Guldberg, et al.
Journal of Experimental & Clinical Cancer Research : CR|January 23, 2025
Stochastic demethylation and redundant epigenetic suppressive mechanisms generate highly heterogeneous responses to pharmacological DNA methyltransferase inhibitionMie K Jakobsen, Sofie Traynor, Aaraby Y Nielsen, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Nature Materials|May 26, 2018
Adoptive T cell cancer therapyKarine N Dzhandzhugazyan, Per Guldberg, Alexei F Kirkin
Cancer Investigation|March 21, 2002
Cancer/testis antigens: structural and immunobiological propertiesAlexei F Kirkin, Karine N Dzhandzhugazyan, Jesper Zeuthen
Journal for Immunotherapy of Cancer|December 4, 2025
Adoptive cell transfer therapy with ex vivo primed peripheral lymphocytes in combination with chemotherapy in locally advanced or metastatic triple-negative breast cancer: the ImmunoBreast phase Ib clinical trialOdd Lilleng Gammelgaard, Sidse Ehmsen, Anne Marie Bak Jylling, et al.
Molecular Cancer|January 6, 2024
Adoptive cell transfer therapy with ex vivo primed peripheral lymphocytes in combination with anti-PDL1 therapy effectively inhibits triple-negative breast cancer growth and metastasisOdd L Gammelgaard, Mikkel G Terp, Alexei F Kirkin, et al.
Neuro-Oncology Advances|November 12, 2021
A randomized phase II trial of efficacy and safety of the immunotherapy ALECSAT as an adjunct to radiotherapy and temozolomide for newly diagnosed glioblastomaKatja Werlenius, Giuseppe Stragliotto, Michael Strandeus, et al.
Nature Communications|March 8, 2018
Adoptive cancer immunotherapy using DNA-demethylated T helper cells as antigen-presenting cellsAlexei F Kirkin, Karine N Dzhandzhugazyan, Per Guldberg, et al.
Journal of Experimental & Clinical Cancer Research : CR|January 23, 2025
Stochastic demethylation and redundant epigenetic suppressive mechanisms generate highly heterogeneous responses to pharmacological DNA methyltransferase inhibitionMie K Jakobsen, Sofie Traynor, Aaraby Y Nielsen, et al.
Pageof 1